Levi & Korsinsky has commenced an investigation into Option Care Health Inc. regarding potential securities law violations. The action follows the company's Q1 2026 earnings report, which showed a revenue shortfall and led to updated full-year guidance.
Law firm Levi & Korsinsky has commenced an investigation into Option Care Health Inc. concerning potential violations of federal securities laws. The probe follows the company's first-quarter 2026 earnings report, which revealed revenue that fell short of analyst expectations and prompted the company to update its full-year financial guidance.
The investigation into Option Care Health (NASDAQ: OPCH) was announced on April 30, 2026, adding legal pressure to the company as it navigates what its CEO called a mixed financial performance. The healthcare provider reported first-quarter net revenue of $1.35 billion, a slight increase from $1.33 billion in the same period last year.
"The first quarter reflected a mixed performance for our business, and we are not satisfied with our revenue growth momentum,” John C. Rademacher, President and CEO of Option Care Health, said in a statement. “We are an execution-driven organization and are taking decisive actions to re-accelerate our growth trajectory."
For the quarter ended March 31, Option Care Health’s adjusted EBITDA fell to $104.8 million from $111.8 million year-over-year, while adjusted diluted earnings per share remained flat at $0.40. The company updated its full-year 2026 guidance, now expecting net revenue between $5.5 billion and $5.7 billion and adjusted EBITDA in the range of $470 million to $490 million.
The combination of a revenue miss and a securities investigation creates significant uncertainty for investors, raising questions about the company's growth prospects and potential legal liabilities. The investigation by Levi & Korsinsky will focus on whether the company may have issued misleading information to the investing public.
Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S., with over 8,000 team members. The company plans to host a conference call on April 30, 2026, to discuss the quarterly results.
The investigation introduces a new layer of risk for shareholders, which could result in legal expenses and divert management's focus from addressing the underlying growth issues. Investors will now be closely watching for any formal complaints filed by the law firm and the company's official response, with the second-quarter earnings report serving as the next major data point on its operational turnaround.
This article is for informational purposes only and does not constitute investment advice.
